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Oral anticoagulation in atrial ﬁbrillation (AF) is important for stroke prevention. Warfarin,
one of the commonly used vitamin K antagonists (VKAs), is underused in clinical practice
due to its well-known limitations and complexity. Identiﬁcation of patients at high risk of
bleeding and weighing up the embolism and bleeding risk can help to reﬁne anticoagulation to
minimize bleeding risk. New oral anticoagulants with diﬀerent mechanisms of action may
replace the VKAs for a number of indications, especially AF. The oral direct thrombin and Xa
inhibitors are furthest along in development. Dabigatran etexilate, a thrombin inhibitor, has
recently gained a class I recommendation as an alternative option to anticoagulants for
prevention of stroke in patients with AF. The percutaneous transcatheter closure of left atrial
appendage has been successfully developed in recent years for reducing the future stroke risk.
On the basis of the recent progress, we suggest to improve warfarin therapy and balance the
stroke prevention and bleeding risk. Clinicians may beneﬁt from these new insights into
anticoagulation in AF.
(J Arrhythmia 2011; 27: 186–192)
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Introduction
Atrial ﬁbrillation (AF) is the most common
arrhythmia encountered in clinical practice. Many
patients with AF receive no prophylactic anticoagu-
lants in spite of strong evidence supporting the
eﬃcacy of anticoagulants in preventing throm-
boembolism related to AF.1,2) The vitamin K
antagonists (VKAs), especially warfarin as the most
widely used oral anticoagulant (OAC), is underused
in clinical practice due to its well-known limitations
and complexity.2) In order to help clinicians choose
appropriate anticoagulation strategy, the recent ESC
guidelines have recommended several scoring sys-
tems to grade the risk of stroke or bleeding among
patients with non-valvular AF, according to the
presence of coexisting clinical factors.3) Several new
oral anticoagulant medications, which are designed
to be given in ﬁxed doses without coagulation
monitoring, are being developed rapidly and may
replace warfarin in the future. This review aims to
provide new insights into recent progress in anti-
coagulation therapy of AF as well as novel oral
anticoagulants.
Risk schemes for stroke and thrombo-embolism
CHADS2 score [congestive heart failure, hyper-
tension, age 75, diabetes, stroke (doubled)] is one
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widely used risk scheme for predicting stroke, in
which 2 points are assigned for a history of stroke or
TIA and 1 point each is assigned for age 75 years,
a history of hypertension, diabetes, or recent cardiac
failure.4) This scheme is simple and can easily be
applied in general clinical practice. However, some
data have suggested that this risk scheme is only
moderately accurate at separating patients into
diﬀerent categories of stroke risk.5–7) The new
2010 ESC guidelines on AF recommended a new
risk scheme—CHA2DS2VASC score [congestive
heart failure, hypertension, age 75, diabetes,
stroke, vascular disease, age 65–74, and sex category
(female)], in which age is weighted diﬀerently, and
female sex and a history of vascular disease are
considered to be signiﬁcant risk factors for stroke.6)
Recently, a few studies compared the performance
of the CHA2DS2VASC score with the CHADS2
score. The results of C statistics showed that the new
scheme CHA2DS2VASC does seem to be better than
CHADS2 at identifying patients at truly low risk for
thromboembolism.7,8) Because age 65 or more and
female sex are considered relevant risk factors, the
people who meet the ‘‘truly low risk’’ criteria are
men under 65. Therefore, the CHA2DS2VASC based
approach to assessing stroke risk is recommended to
be used in patients with multiple clinically-relevant
non-major risk factors for stroke.
Bleeding risk assessments in AF patients
Although the clinical beneﬁt of OAC clearly
outweighs the bleeding risk of OAC therapy in AF
patients, major bleeding events (especially intra-
cerebral haemorrhage) may be devastating when
they do occur. However, clinical scores for bleeding
risk assessment are not nearly as well validated as
stroke risk scores in ‘‘real-world’’ clinical practice.
Established bleeding risk factors include age, inter-
national normalized ratio (INR) range, prior stroke,
history of bleeding, anaemia, co-morbidities (uncon-
trolled hypertension, hepatic and renal insuﬃcien-
cy), and use of concomitant medication or alcohol.
Based on a combination of treatment- and person-
associated factors, several bleeding risk predicting
rules have been proposed, including the modiﬁed
Outpatient Bleeding Risk Index (mOBRI),9) the
HEMORR2HAGES score,10) the HAS-BLED
score,11) the ATRIA score (data from the ATRIA
study presented in abstract form). These bleeding
risk schemes may help physicians stratify patients
into categories of increasing risk of bleeding (low,
intermediate, and high risk). The HAS-BLED score
has been recommended by the 2010 ESC guidelines
for the management of AF and the Canadian
guidelines12) for its good predictive accuracy.6,11)
Therefore, bleeding risk stratiﬁcation should be
considered, either prior to starting or during anti-
coagulation treatment in AF patients.
Existing problems with VKAs
For as many as 50 years, VKAs remain the only
form of oral anticoagulant medication approved for
long-term use. Warfarin, the most commonly used
VKAs, has been an important drug for the prevention
of thromboembolic events in AF patients. Solid
evidence exists that warfarin reduces AF-related
stroke risk by two-thirds compared to placebo
(64%), whereas aspirin decreases stroke risk only
by 22%.13) Warfarin also reduces the risk of stroke
by 42% compared with the combination of acetyl-
salicylic acid and clopidogrel, as recently shown in
the ACTIVE W trial.14) However, a recent system-
atic review still demonstrates the underuse of oral
anticoagulation therapy for real-world atrial ﬁbrilla-
tion patients with an elevated risk of stroke.2) The
widespread underuse of warfarin for AF patients can
be attributed to its well-known limitations and
complexity:
1) The frequent and specialized blood test mon-
itoring is required because:
a. the dose response is unpredictable;
b. warfarin has a narrow therapeutic INR range
of 2.0–3.0, above which or below which
bleeding or thromboembolism can occur;
c. the metabolism of warfarin is aﬀected by
multiple factors, like diet, concomitant
conditions (smoking and alcohol use),
drugs, and genetic polymorphisms—varia-
tions in two genes, the cytochrome P450
family 2 subfamily C polypeptide 9 enzyme
(CYP2C9) gene and the vitamin K epoxide
reductase complex 1 (VKORC1) gene, con-
tribute signiﬁcantly to the variability among
patients in dose requirements for warfarin.
2) The inter- and intra-patient variability of
eﬀective dose causes many patients to spend
large amounts of time outside the therapeutic
INR window, which increases the risk of
bleeding or thromboembolism.
3) The side eﬀect associated with the use of
warfarin, hemorrhage, could be serious and
devastating. The fear of iatrogenic hemarrhage
is one of the most important reasons why
physicians do not prescribe warfarin for a
substantial number of AF patients who are
likely to beneﬁt from it.15)
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Other limitations include delayed onset and oﬀset
of action, slow reversibility of anticoagulant eﬀect,
and requirement of labor-intensive follow up, expert
dose management, and frequent patient communica-
tion.
New oral anticoagulants
The limitation and complexity of VKAs have led
clinicians, patients, and investigators to search for
alternative agents. An anticoagulant that is non-
inferior to warfarin in reducing thromboembolic
events, has a low rate of bleeding risk (especially
of major bleeding), few drug interactions, a wide
therapeutic index, and no need for laboratory
monitoring, may represent a signiﬁcant improvement
over warfarin and other currently available VKAs.
Recently, two classes of new oral anticoagulant
drugs are being developed for stroke prevention in
AF— the oral direct thrombin inhibitors and the oral
factor Xa inhibitors.
Dabigatran Etexilate—A direct thrombin inhib-
itor: Dabigatran etexilate is an oral prodrug and is
rapidly converted to an active direct thrombin
inhibitor after oral administration and hepatic proc-
essing independent of the cytochrome P-450.16)
Dabigatran has a low potential for drug-drug and
drug-diet interactions and is predominantly renally
excreted. Dabigatran directly inhibits both free and
clot-bound thrombin, and is administered in ﬁxed
doses without laboratory monitoring of anticoagu-
lation intensity. Dabigatran etexilate (Pradaxa,
Boehringer Ingelheim) has been approved in Europe
and Canada since 2008 for venous thromboembolism
(VTE) prophylaxis in hip and knee surgery patients
based on clinical evidence of three major phase-3
studies: RE-MODEL,17) RE-MOBILIZE18) and RE-
NOVATE.19) The clinical evidence for the eﬃcacy
of dabigatran in patients with nonvalvular AF comes
from the multinational, randomized, parallel group
the RE-LY trial,20) which compared 2 blinded doses
of dabigatran (110mg twice daily and 150mg twice
daily) with open-label warfarin (dosed to target an
INR of 2 to 3) in nonvalvular AF patients at a higher
risk of stroke. The RE-LY trial demonstrated that as
compared with warfarin, dabigatran 150mg twice
daily was associated with lower rates of stroke and
systemic embolism (1.69% vs. 1.11%, P < 0:001 for
superiority) but similar rates of major hemorrhage
(3.36% vs. 3.31%). Dabigatran 110mg twice daily
was associated with similar rates of stroke and
systemic embolism and lower rates of major hem-
orrhage as compared to warfarin. Dabigatran etex-
ilate was approved by the FDA for the prevention of
stroke and systemic embolism in patients with
nonvalvular AF on October 19, 2010. Then, dabiga-
tran was added to the U.S. guidelines with a Class I
recommendation on March 15, 2011.21) Dabigatran
has been the ﬁrst new OAC to become available for
clinical use in >50 years.
Oral direct factor Xa inhibitors: Rivaroxaban is
the ﬁrst available orally active direct factor Xa
inhibitor. Rivaroxaban inhibits both the ‘‘free’’ and
prothombinase-complex-bound forms of Factor
Xa.22) Rivaroxaban does not inhibit thrombin, and
no eﬀects on platelets have been demonstrated.
Rivaroxaban is metabolized partially by cytochrome
P450 (CYP) 3A4 and is partially eliminated by the
kidney and fecal routes.23) Rivaroxaban is currently
approved in Europe and Canada for venous thrombo-
embolism prevention following orthopedic surgery.
The ROCKET AF trial24) is a phase III trial of
rivaroxaban for prevention of stroke and embolism
in more than 14,000 patients with nonvalvular AF.
The preliminary results from ROCKET AF trial
presented at the American Heart Association (AHA)
2010 Scientiﬁc Sessions showed that rivaroxaban
was noninferior to warfarin without an increase in
major bleeding. However, rivaroxaban is suggested
as an ‘‘alternative’’ to warfarin in moderate- or high-
risk patients with AF due to poor adherence with
rivaroxaban.
Apixaban is also an oral direct factor Xa inhibitor
administered twice daily. Apixaban (2.5mg BID)
was compared with aspirin (81–324mg QD) for
stroke prevention in AF (AVERROES trial) in more
than 6000 patients who have failed or who are
unsuitable for warfarin. This study was recently
stopped due to the superiority of apixaban over
aspirin in these patients, without excess bleeding.
The ARISTOTLE phase III study25) compares
apixaban (5mg BID) to warfarin for stroke preven-
tion in more than 18,000 AF patients with a median
CHADS2 score of 2. This randomized, event driven,
double-blind, noninferiority study will be reported in
2011. Edoxaban, another oral factor Xa inhibitor, has
recently been studied in a phase III trial (ENGAGE
AF-TIMI 48) comparison to warfarin for the pre-
vention of thromboembolism in AF patients.
The future for anticoagulation in AF
1. Are new oral anticoagulants really better?
New oral anticoagulant agents have many poten-
tial advantages over warfarin, including their rapid
onset of action, predictable therapeutic eﬀect, and
limited drug-drug interactions. These advantages
may allow the physician to potentially use agents
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without routine coagulation monitoring. All of this
may result in a greater use of anticoagulants,
especially for conditions like AF, which is widely
undertreated.
However, several potential issues will be encoun-
tered as these new oral anticoagulants will become
available in the near future. Some potential compli-
cations including liver enzyme elevation and cardiac
irregularities have been reported in the use of
dabigatran, rivaroxaban and apixaban.26) Because
dabigatran and rivaroxaban are predominantly elim-
inated by the kidney, use of these medications should
be used cautiously in elderly patients who may have
an age-related reduction in drug clearance and in
those patients with marginal renal clearance. There
are also known drug interactions with some of these
new agents. Dabigatran is contraindicated with the
concomitant use of quinidine, verapamil, clarithro-
mycin, or amiodarone, and other P-glycoprotein
inhibitors.26) The lack of a requirement for monitor-
ing makes it diﬃcult to tailor the intensity of
anticoagulant therapy, or determine if the speciﬁc
therapy has failed. Short half-lives of new agents
also make the adherence of medication extremely
important, especially for AF patients. The absence of
speciﬁc antidotes may be problematic for patients
who are at a high risk of bleeding or for those who
present with a bleed. Fortunately, the use of fresh
frozen plasma and prothrombin concentrates have
been shown to be able to reverse anticoagulation
with several of the new agents.27) In addition, new
agents will be signiﬁcantly more expensive than
warfarin, and patients may not take them due to
ﬁnancial stresses. Therefore, it remains to be
established whether newer oral anticoagulants will
be better alternatives to the current standard-of-care
in ‘‘real world’’ clinical practices.
2. What can we do to improve warfarin therapy
Warfarin still remains the mainstay of treatment
for patients with nonvalvular AF. There is still a
need for developing methods to improve the care of
warfarin-treated patients. Diﬀerent interventions
have been proposed in the past, which include
specialized anticoagulation clinics, home INR self-
monitoring, adherence interventions, and dosing
algorithms.28) Anticoagulation clinics have been
shown to improve anticoagulation control and out-
comes.29) Home INR monitoring seems not to delay
the time to a ﬁrst stroke, major bleeding episode, or
death,30) but self-monitoring and self-management of
dosing improve the quality of oral anticoagulation.31)
Dosing algorithms that incorporate genotypes and
clinical characteristics might be useful during the
initiation phase of warfarin therapy. Most algorithms
share in common the inclusion of age, measures of
body size (such as body surface area or weight), the
genetic variants of CYP2C9 and VKORC1, and
some additional variables like diabetes, sex, inter-
acting medications, target INR, and valve replace-
ment.28) Recently, a pharmacogenetic dosing algo-
rithm using variations in CYP2C9 and VKORC1
genes produces recommendations that are signiﬁ-
cantly closer to the required stable therapeutic dose
than those derived from a clinical algorithm or a
ﬁxed-dose approach.32) When a steady state is
reached, adherence to interventions might be most
beneﬁcial and logistically applicable during main-
tenance phase.
Finally, it might be helpful to identify an appro-
priate anticoagulation intensity for reducing the risk
of hemorrhage or thromboembolism in diﬀerent
populations. Although the overwhelming evidence
supports that an INR of 2.0–3.0 is likely the optimal
range for prevention of stroke and systemic embolism
in patients with non-valvular AF, there is controversy
as to whether the low intensity of anticoagulation
therapy will be as eﬀective as the standard intensity.
Low intensity therapy of warfarin (INR 1.5–2.0) has
been reported to be safe and eﬀective for prevention
of systemic embolism.33,34) In elderly Japanese with
AF,35) the low intensity warfarin (INR1.5–2.1) treat-
ment seems to be associated with a low rate of
stroke (1.7% per year) and signiﬁcantly low bleeding
complications (0% per year) as compared with
conventional intensity treatment (INR2.2–3.5). An-
other study of Japanese patients also showed that low
intensity of warfarin therapy (INR1.5–2.0) is eﬃca-
cious in treating left atrial thrombus formation in
patients with nonvalvular AF.36) For elderly patients,
the new 2010 ESC guidelines on AF recommended a
lower target INR range (1.8–2.5) with low large trial
evidence base.
3. Left atrial appendage closure
In atrial ﬁbrillation, blood clots arise from the left
atrial appendage (LAA) in more than 90% of cases.37)
Surgical closure of the LAA at the time of mitral
valve surgery has been practiced and recommended
by guidelines,38) but with suboptimal results.39) The
percutaneous transcatheter LAA exclusion has been
successfully developed in recent years for reduction
of future stroke risk.40,41) The PROTECT AF study
was designed to demonstrate the safety, eﬃcacy, and
non-inferiority of the Watchman device compared
to chronic warfarin therapy in those patients with
nonvalvular AF who are eligible for long-term
OAC.41) Device closure of the LAA using the
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Watchman device (Atritech, Plymouth, MN) was
associated with a reduction in hemorrhagic stroke
risk vs. warfarin, and all-cause stroke and all-cause
mortality outcomes were noninferior to warfarin.
However, an important risk of serious procedural
complications was observed in the device group, but
these have decreased over time with procedural
modiﬁcations and enhanced training. The Amplatzer
Cardiac Plug (ACP) is one of new LAA closure
devices, and initial results are encouraging.42) There-
fore, percutaneous closure of the LAA is a novel
alternative for the treatment of patients with AF at a
high risk of stroke, in whom long-term anticoagu-
lation therapy is not possible or not desired.
Maintenance of sinus rhythm
The best therapy for prevention of stroke might
be the successful restoring and maintenance of
sinus rhythm in AF patients, which could also avoid
the adverse bleeding events of anticoagulation.
Dronedarone, a new antiarrhythmic drug speciﬁcally
developed for the management of AF, has been
recommended by 2010ESC3) and 2011AHA guide-
lines for the prevention of recurrent AF and main-
tenance of sinus rhythm in patients with recurrent
paroxysmal or persistent AF. Because of the better
safety and potential outcome beneﬁt, dronedarone
can be administrated as the ﬁrst antiarrhythmic
option in AF patients without structural heart disease
and in stable patients with underlying cardiovascular
disease, including ACS, chronic stable angina,
hypertensive heart disease, and stable NYHA class
I–II heart failure. The development of new anti-
arrhythmic drugs may bring new light to the
management of AF. However, the eﬃcacy and
safety of dronedarone still need to be assessed in
real world clinical practice.
In both the ACC/AHA/HRS and the ESC new
guidelines, catheter ablation gains a improved
recommendation (class I) when performed in expe-
rienced centers for selected patients who have failed
a trial of antiarrhythmic medication and have normal
or mildly dilated left atria, normal or mildly reduced
LV function, and no severe pulmonary disease. For
symptomatic persistent and paroxysmal AF in
patients with signiﬁcant left atrial dilation or with
signiﬁcant left ventricular dysfunction, catheter
ablation can also be considered as a reasonable
treatment option.
Balancing the stroke prevention and bleeding risk
Both the risk for stroke and the risk for bleeding
are not homogenous in AF. Because of the bleeding
risk of anticoagulation therapy in patients with AF,
stroke risk stratiﬁcation schemes have been devised
to identify ‘‘high risk’’ AF patients for whom the
absolute beneﬁts of OAC exceed its risks. However,
it has been increasingly recognized that many of the
known factors that increase stroke risk overlap with
bleeding risk factors.43) Both stroke and bleeding risk
assessment have been recommended by 2010ESC
guidelines before deciding anticoagulation strategy
in AF patients (CHA2DS2VASC and HAS-BLED
score). In fact, most patients with AF, including
those at high bleed risk, can beneﬁt from anti-
coagulant treatment, because bleeding risk is sig-
niﬁcantly lower than stroke risk.44) The selection of
OAC or ASA, as well as dosage, should be made
cautiously to preserve the delicate balance between
stroke risk and bleeding. Furthermore, additional
bleeding risk should be considered in some special
situations, such as periablation, peri-devices (im-
plantable cardioverter-deﬁbrillator, pacemakers),
acute coronary syndrome or percutaneous coronary
intervention, and surgical procedures.
In conclusion, the anticoagulation therapy should
be stressed in real world practice because the
bleeding risk is almost inevitably lower than stroke
risk in patients with AF. The widespread underuse of
warfarin implicates a great need of interventions to
improve warfarin therapy. In addition, identiﬁcation
of patients at high risk of bleeding and weighing up
the embolism and bleeding risk can help to reﬁne
anticoagulation to minimize bleeding risk. The new
oral anticoagulants have the potential to play a
signiﬁcant role in a wide range of clinical settings.
Also, non-pharmacological methods to prevent
stroke (like LAA) should be further developed in
the future.
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